BlackRock reports 7.2% stake in Cytek Biosciences

BlackRock, Inc. amended its Schedule 13G to report beneficial ownership of 9,356,551 shares of Cytek Biosciences, Inc. The filing states 9,356,551 shares were beneficially owned, representing 7.2% of the outstanding common stock as of 06/30/2026.

Rhea-AI Filing Summary

BlackRock, Inc. amended its Schedule 13G to report beneficial ownership of 9,356,551 shares of Cytek Biosciences, Inc. The filing states 9,356,551 shares were beneficially owned, representing 7.2% of the outstanding common stock as of 06/30/2026. The report shows sole voting power of 9,228,737 shares and sole dispositive power of 9,356,551. The filing is signed by a BlackRock managing director on 07/08/2026 and discloses that various persons may have rights to dividends or sale proceeds.

Insights

Institutional Ownership Analyst

BlackRock discloses a 7.2% economic stake in Cytek as of 06/30/2026.

The filing lists 9,356,551 shares beneficially owned with 9,228,737 shares of sole voting power. This is a snapshot of ownership rather than a transaction.

Future filings may update the position; cash‑flow treatment or trading intent is not stated in the excerpt.

Key Figures

Beneficially owned shares: 9,356,551 shares Percent of class: 7.2% Sole voting power: 9,228,737 shares +3 more

6 metrics

Beneficially owned shares 9,356,551 shares Amount beneficially owned reported on Schedule 13G/A

Percent of class 7.2% Percent of outstanding common stock as reported

Sole voting power 9,228,737 shares Number with sole power to vote as stated in Item 4

Sole dispositive power 9,356,551 shares Number with sole power to dispose as stated in Item 4

Ownership snapshot date 06/30/2026 Date tied to the reported ownership figures

Filing signature date 07/08/2026 Date the Schedule 13G/A amendment was signed

Key Terms

Schedule 13G/A, Beneficially owned, Sole dispositive power, Investment Company Act, +1 more

5 terms

Schedule 13G/A regulatory

"Amendment No. 5; the cover identifies the form as Schedule 13G/A"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Item 4(a) lists the "Amount beneficially owned: 9356551""

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power financial

"Item 4(iii) lists "Sole power to dispose... 9356551""

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Investment Company Act regulatory

"Item 6 references shareholders of an investment company registered under the Investment Company Act of 1940"

The Investment Company Act is a law that sets rules for businesses whose main activity is managing and selling pooled money, such as mutual funds and other investment funds. It matters to investors because it requires clear reporting, limits managers from putting their own interests ahead of clients, and mandates safekeeping and oversight of assets—similar to safety inspections and traffic rules that help keep shared vehicles reliable and trustworthy.

Exhibit 99 regulatory

"Item 7 and Exhibit Information reference Exhibit 99: Item 7"

FAQ

What stake does BlackRock hold in Cytek Biosciences (CTKB)?

BlackRock beneficially owns 9,356,551 shares, representing 7.2% of Cytek Biosciences' common stock as of 06/30/2026. The filing shows BlackRock holds sole voting power over 9,228,737 shares and sole dispositive power over the full 9,356,551 shares.

Which date does the Schedule 13G/A ownership snapshot use for CTKB?

The ownership figures are reported as of 06/30/2026 in the amendment. The Schedule 13G/A is signed on 07/08/2026, which attests to the reported snapshot and filing date.

Does the filing state who receives proceeds or dividends for BlackRock's CTKB shares?

The filing states that various persons have rights to dividends or sale proceeds but does not identify any single person with more than 5% interest. It notes no single outside person holds over 5% of the shares referenced.

Who signed the Schedule 13G/A for BlackRock regarding CTKB?

The amendment is signed by Spencer Fleming, listed as Managing Director, with the signature date of 07/08/2026. Exhibit references include a Power of Attorney and Item 7 exhibit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/08/2026 - 11:13 AM Accepted by SEC EDGAR 07/08/2026 - 11:12 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

Cytek Biosciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

23285D109

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 23285D109

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 9,228,737.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 9,356,551.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,356,551.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.2 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cytek Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 47215 LAKEVIEW BOULEVARD FREMONT CA 94538
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 23285D109
Item 4.	Ownership
(a)	Amount beneficially owned: 9356551
(b)	Percent of class: 7.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 9228737
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 9356551
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Cytek Biosciences, Inc.. No one person's interest in the common stock of Cytek Biosciences, Inc. is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/08/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7